18 human secreted proteins

摘要

Nucleic acid molecules (NAM1) encoding 18 human secreted human proteins (PEP1), are new. NAM1 comprises one of 18 defined nucleotide (NT) sequences (SEQs) ((N1)-(N18)) or a polyNT encoded by the cDNA SEQ included in ATCC PTA-536 which is hybridizable to (N1)-(N18). PEP1 comprises one of 18 defined amino acid (AA) SEQs ((A1)-(A18)). All sequences are given in the specification. Independent claims are included for the following: (1) an isolated nucleic acid molecule (NAM1) comprising a polyNT having a NT SEQ at least 95 % identical to a SEQ selected from: (a) a polyNT fragment from one of 18 defined NT SEQs ((N1)-(N18)) given in the specification or a polyNT fragment of the cDNA SEQ included in ATCC PTA-536 which is hybridizable to (N1)-(N18); (b) a polyNT encoding a polypeptide fragment from one of 18 defined AA SEQs ((A1)-(A18)) given in the specification or a polypeptide fragment encoded by the cDNA SEQ included in ATCC PTA-536 which is hybridizable to (N1)-(N18); (c) a polyNT encoding a polypeptide domain of (A1)-(A18) or a polypeptide domain encoded by the cDNA SEQ included in ATCC PTA-536 which is hybridizable to (N1)-(N18); (d) a polyNT encoding a polypeptide group of (A1)-(A18) or a polypeptide group encoded by the cDNA SEQ included in ATCC PTA-536 which is hybridizable to (N1)-(N18); (e) a polyNT encoding a polypeptide of (A1)-(A18) or a polypeptide group encoded by the cDNA SEQ included in ATCC PTA-536 which is hybridizable to (N1)-(N18) and which is biologically active; (f) a polyNT variant of (N1)-(N18); (g) a polyNT which is an allelic variant of (N1)-(N18); (h) a polyNT which encodes a species homologue of (A1)-(A18); and/or (i) a polyNT capable of hybridizing under stringent condition to any of the polyNTs specified in (a)-(h) (above), and which does not hybridize under stringent conditions to a nucleic acid molecule comprising a SEQ of only A residues or T residues; (2) a vector (VEC1) comprising NAM1; (3) a method (M1) of making a recombinant host cell comprising NAM1; (4) a recombinant host cell (CELL1) produced by (M1); (5) an isolated polypeptide (PEP1) comprising an AA SEQ at least 95% identical to a SEQ selected from: (a) a polypeptide fragment of (A1)-(A18) or the encoded SEQ included in ATCC PTA-536; (b) a polypeptide fragment of (A1)-(A18) or the encoded SEQ included in ATCC PTA-536 which has biological activity; (c) a polypeptide domain of (A1)-(A18) or the encoded SEQ included in ATCC PTA-536; (d) a polypeptide group of (A1)-(A18) or the encoded SEQ included in ATCC PTA-536; (e) a secreted form of (A1)-(A18) or the encoded SEQ included in ATCC PTA-536; (f) a full length protein of (A1)-(A18) or the encoded SEQ included in ATCC PTA-536; (g) a variant of (A1)-(A18); (h) an allelic variant of (A1)-(A18); and/or (i) a species homologue of (A1)-(A18); (6) an isolated antibody that binds specifically to PEP1; (7) a recombinant host cell (CELL2) that expresses PEP1; (8) a method (M2) of making an isolated polypeptide comprising: (a) culturing CELL2 under conditions in which the polypeptide is expressed; and (b) recovering the polypeptide; (9) the polypeptide produced by M2; (10) a method (M3) for preventing, treating or ameliorating a medical condition, comprising administering NAM1 or PEP1 to a mammalian subject; (11) a method (M4) of diagnosing a pathological condition or susceptibility to a pathological condition in a subject, comprising: (a) determining the presence or absence of a mutation in NAM1; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of the mutation; (12) a method (M5) of diagnosing a pathological condition or a susceptibility to a pathological condition, comprising: (a) determining the presence or amount of expression of PEP1 in a biological sample; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of PEP1; (13) a method (M6) for identifying a binding partner of PEP1, comprising: (a) contacting PEP1 with a candidate binding partner; and (b) determining whether the binding partner effects an activity of the polypeptide; (14) the gene corresponding to the cDNA SEQ (A1)-(A18); (15) a method (M7) of identifying an activity in a biological assay, comprising: (a) expressing (N1)-(N18) in a cell; (b) isolating the supernatant; (c) detecting an activity in a biological assay; and (d) identifying the protein in the supernatant having the activity; and (16) the product of (M7). ACTIVITY : Immunomodulatory; antisclerotic; dermatological; immunosuppressive; antiinflammatory; anti-HIV; immunostimulant; cytostatic; cardiant; vascular; anti-angiogenic; ophthalmological; neuroprotectant; nootropic; anticonvulsant; antialzheimers; antiparkinsonian; antimicrobial; vulnerary. Assays are described however no biological data is given. MECHANISM OF ACTION : Gene therapy; vaccine.